Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug development in metabolic dysfunction-associated steatohepatitis (MASH).

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab at the 98th Congress of the German Society of Neurology in Berlin. The ...

Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s acceptance of an Investigational New Drug application for a cereblon E3 ligase ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (extended-release) tablets led to meaningful improvements for adults living with ...

Adocia has announced the filing of a patent for its new long-acting peptide platform, AdoXLong, aimed at improving treatment options for diabetes and obesity. The French biopharmaceutical company said ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its lead ATAC candidate for relapsed or refractory multiple myeloma. The company ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of nephropathic cystinosis – a rare, progressive and life-limiting condition ...

The Christie NHS Foundation Trust has completed a four-month digital transformation project using Netcall’s Liberty Spark to map over 70 care processes across nine patient pathways.

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients with Duchenne muscular dystrophy (DMD), including first data from the ...

Theolytics has named Matilde Saggese as its new Chief Medical Officer, as the Oxford-based biotech company accelerates clinical development of its lead oncolytic immunotherapy, THEO-260.